439 related articles for article (PubMed ID: 14610016)
1. Cost-effectiveness of coronary stenting and abciximab for patients with acute myocardial infarction: results from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trial.
Bakhai A; Stone GW; Grines CL; Murphy SA; Githiora L; Berezin RH; Cox DA; Stuckey T; Griffin JJ; Tcheng JE; Cohen DJ;
Circulation; 2003 Dec; 108(23):2857-63. PubMed ID: 14610016
[TBL] [Abstract][Full Text] [Related]
2. Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
Lansky AJ; Pietras C; Costa RA; Tsuchiya Y; Brodie BR; Cox DA; Aymong ED; Stuckey TD; Garcia E; Tcheng JE; Mehran R; Negoita M; Fahy M; Cristea E; Turco M; Leon MB; Grines CL; Stone GW
Circulation; 2005 Apr; 111(13):1611-8. PubMed ID: 15811868
[TBL] [Abstract][Full Text] [Related]
3. The economics of adjunctive therapies in coronary angioplasty: drugs, devices, or both?
Oh PI; Cohen EA; Mittmann N; Seung SJ
Can J Clin Pharmacol; 2004; 11(2):e202-11. PubMed ID: 15520474
[TBL] [Abstract][Full Text] [Related]
4. Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial).
Dangas G; Aymong ED; Mehran R; Tcheng JE; Grines CL; Cox DA; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Lansky AJ; Stone GW;
Am J Cardiol; 2004 Oct; 94(8):983-8. PubMed ID: 15476608
[TBL] [Abstract][Full Text] [Related]
5. Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
Guagliumi G; Stone GW; Cox DA; Stuckey T; Tcheng JE; Turco M; Musumeci G; Griffin JJ; Lansky AJ; Mehran R; Grines CL; Garcia E
Circulation; 2004 Sep; 110(12):1598-604. PubMed ID: 15353506
[TBL] [Abstract][Full Text] [Related]
6. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
Tcheng JE; Kandzari DE; Grines CL; Cox DA; Effron MB; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Fahy M; Lansky AJ; Mehran R; Stone GW;
Circulation; 2003 Sep; 108(11):1316-23. PubMed ID: 12939213
[TBL] [Abstract][Full Text] [Related]
7. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.
Stone GW; Grines CL; Cox DA; Garcia E; Tcheng JE; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Carroll JD; Rutherford BD; Lansky AJ;
N Engl J Med; 2002 Mar; 346(13):957-66. PubMed ID: 11919304
[TBL] [Abstract][Full Text] [Related]
8. Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial.
Nikolsky E; Aymong ED; Halkin A; Grines CL; Cox DA; Garcia E; Mehran R; Tcheng JE; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Cohen DA; Negoita M; Lansky AJ; Stone GW
J Am Coll Cardiol; 2004 Aug; 44(3):547-53. PubMed ID: 15358018
[TBL] [Abstract][Full Text] [Related]
9. Feasibility and implications of an early discharge strategy after percutaneous intervention with abciximab in acute myocardial infarction (the CADILLAC Trial).
Kandzari DE; Tcheng JE; Cohen DJ; Bakhai A; Grines CL; Cox DA; Effron M; Stuckey T; Griffin JJ; Turco M; Carroll JD; Fahy M; Mehran R; Stone GW;
Am J Cardiol; 2003 Oct; 92(7):779-84. PubMed ID: 14516875
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial.
Cohen DJ; Bakhai A; Shi C; Githiora L; Lavelle T; Berezin RH; Leon MB; Moses JW; Carrozza JP; Zidar JP; Kuntz RE;
Circulation; 2004 Aug; 110(5):508-14. PubMed ID: 15262844
[TBL] [Abstract][Full Text] [Related]
11. Cost-efficacy in interventional cardiology; results from the EPISTENT study. Evaluation of Platelet IIb/IIIa Inhibitor For Stenting Trial.
Zwart-van Rijkom JE; van Hout BA
Eur Heart J; 2001 Aug; 22(16):1476-84. PubMed ID: 11482921
[TBL] [Abstract][Full Text] [Related]
12. When is door-to-balloon time critical? Analysis from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) and CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trials.
Brodie BR; Gersh BJ; Stuckey T; Witzenbichler B; Guagliumi G; Peruga JZ; Dudek D; Grines CL; Cox D; Parise H; Prasad A; Lansky AJ; Mehran R; Stone GW
J Am Coll Cardiol; 2010 Jul; 56(5):407-13. PubMed ID: 20650362
[TBL] [Abstract][Full Text] [Related]
13. Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial).
Stuckey TD; Stone GW; Cox DA; Tcheng JE; Garcia E; Carroll J; Guagliumi G; Rutherford BD; Griffin JJ; Turco M; Lansky AJ; Mehran R; Fahy M; Brodie BR; Grines CL;
Am J Cardiol; 2005 Jan; 95(1):1-7. PubMed ID: 15619385
[TBL] [Abstract][Full Text] [Related]
14. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up.
Montalescot G; Antoniucci D; Kastrati A; Neumann FJ; Borentain M; Migliorini A; Boutron C; Collet JP; Vicaut E
Eur Heart J; 2007 Feb; 28(4):443-9. PubMed ID: 17251257
[TBL] [Abstract][Full Text] [Related]
15. Cost and effectiveness of glycoprotein IIb/IIIa-receptor inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
McCollam PL; Foster DA; Riesmeyer JS
Am J Health Syst Pharm; 2003 Jun; 60(12):1251-6. PubMed ID: 12845921
[TBL] [Abstract][Full Text] [Related]
16. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
[TBL] [Abstract][Full Text] [Related]
17. Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: a prospective, multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting alone.
Antoniucci D; Migliorini A; Parodi G; Valenti R; Rodriguez A; Hempel A; Memisha G; Santoro GM
Circulation; 2004 Apr; 109(14):1704-6. PubMed ID: 15066943
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
Bakhai A; Stone GW; Mahoney E; Lavelle TA; Shi C; Berezin RH; Lahue BJ; Clark MA; Lacey MJ; Russell ME; Ellis SG; Hermiller JB; Cox DA; Cohen DJ;
J Am Coll Cardiol; 2006 Jul; 48(2):253-61. PubMed ID: 16843171
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of optimal or "stent-like"balloon angioplasty in acutemyocardial infarction: the CADILLAC trial.
Cox DA; Stone GW; Grines CL; Stuckey T; Cohen DJ; Tcheng JE; Garcia E; Guagliumi G; Iwaoka RS; Fahy M; Turco M; Lansky AJ; Griffin JJ; Mehran R;
J Am Coll Cardiol; 2003 Sep; 42(6):971-7. PubMed ID: 13678914
[TBL] [Abstract][Full Text] [Related]
20. Economic impact of same-day home discharge after uncomplicated transradial percutaneous coronary intervention and bolus-only abciximab regimen.
Rinfret S; Kennedy WA; Lachaine J; Lemay A; Rodés-Cabau J; Cohen DJ; Costerousse O; Bertrand OF
JACC Cardiovasc Interv; 2010 Oct; 3(10):1011-9. PubMed ID: 20965458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
